An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line

Blood

Volumn 104, Issue 1, 2004, Pages 178-183

  Ghetie, Maria Ana ^a   Marches, Radu ^a   Kufert, Stephanie ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CD22 ANTIGEN; DOXORUBICIN; GANGLIOSIDE GM1; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HD37; MONOCLONAL ANTIBODY RFB4; RHODAMINE 123; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE SULFATE;

ARTICLE; BURKITT LYMPHOMA; CELL GROWTH; CELL MEMBRANE; CHEMOSENSITIVITY; CROSS REACTION; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LYMPHOMA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE; WESTERN BLOTTING;

EID: 3042799345     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4255     Document Type: Article

References (25)

1. Gottesman MM, Pastan I. Biochemistry of multidrug-resistance mediated by the multi-drug transporter. Ann Rev Biochem. 1993;62:385-427.
2. Borst P. Multidrug resistant proteins. Semin Cancer Biol. 1997;8:131-134.
3. Germann UA. P-glycoprotein: a mediator of multidrug resistance in tumour cells. Proc Natl Acad Sci U S A. 1996;83:7785-7789.
4. Hamada H, Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986;83:7785-7789.
5. Mechetner EB, Roninson I. Efficient inhibition of P-glycoprotein-mediated multi-drug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992;89:5824-5828.
6. Mechetner EB, Schott B, Morse BS, et al. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci U S A. 1997;94:12908-12913.
7. Fisher G, Lum B, Hausdorff J, Sikic BI. Pharmacological consideration in the modulation of multidrug resistance. Eur J Cancer. 1996;32:1082-1088.
8. Ghetie MA, Picker LJ, Richardson JA, et al. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood. 1994;83:1329-1336.
9. Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug resistant B lymphoma cells. Clin Cancer Res. 1999;5:3920-3927.
10. Chambers TC, McAvoy EM, Jacobs JW, Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990;265:7679-7685.
11. Hardy SP, Goodfellow HR, Valverde MA, et al. Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J. 1995;14:68-75.
12. Garrigues A, Escargueil AE, Orlowski S. The multidrug transpoter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A. 2002;99:10347-10352.
13. Luker G, Pica C, Kumar A, Covey D, Piwnica-Worms D. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry. 2000;39:7651-7661.
14. Lavie Y, Fiucci G, Liscouitch M. Upregulation of caveolar and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem. 1998;273:32380-32383.
15. Demeule M, Jodoin J, Gingras D, Beliveau R. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett. 2000;466:219-224.
16. O'Connor R, Liu C, Ferris CA, et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood. 1995;86:4286-4294.
17. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol. 2000;1:156-159.
18. Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol. 1996;27:251-255.
19. Ferte J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem. 2000;267:277-294.
20. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-162.
21. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997;6:107-118.
22. Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity. 2001;14:169-179.
23. Bradbury LE, Goldmacher VS, Tedder TF. The CD19 signal transduction complex of B lymphocytes. J Immunol. 1993;151:2915-2927.
24. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B-lymphocytes. J Exp Med. 1993;178:1407-1417.
25. Tsitsikov EN, Gutierrez-Ramos JC, Geha RS. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci U S A. 1997;94:10844-10849.